The Science & Practice of Cryoneurolysis

A comprehensive guide for patients and referring clinicians on one of the most exciting non-opioid pain technologies available today.

Chronic pain costs the United States more than $600 billion annually — and most of the burden is carried by the treatments we rely on most: opioids, repeated injections, and surgeries that never quite fix the underlying problem. Cryoneurolysis is not a cure-all, but it may be the most meaningfully different tool we’ve added to the interventional pain armamentarium in years.

THE BASICS

What Is Cryoneurolysis — and How Is It Different?

Cryoneurolysis uses precisely targeted, extreme cold to temporarily disable a specific peripheral nerve — interrupting its ability to transmit nerve signals (relieving pain and spasticity), without drugs, without burning tissue, and without permanent damage.

The technology most widely used in clinical practice today is the iovera° system (Pacira BioSciences), an FDA-cleared handheld device that delivers liquid nitrous oxide through a closed-end microneedle. This creates a focused ice ball at temperatures reaching -88°C at the tip — cold enough to cause a controlled, reversible nerve injury at the axon level, while leaving the structural nerve sheath (endoneurium, perineurium, epineurium) completely intact.

The result is a Sunderland Grade 2 axonotmesis — classically described as “nerve hibernation.” The nerve stops conducting pain immediately. Over weeks to months, the axon regenerates along its intact structural scaffold, restoring full nerve function. No permanent damage. No scar. No neuroma risk.

KEY DISTINCTION

Unlike radiofrequency ablation (RFA), which uses heat (85°C) and causes tissue damage, cryoneurolysis causes NO tissue damage. Unlike cryoablation used for tumors — which is clinically permanent at -140°C — cryoneurolysis is intentionally reversible. This reversibility is a feature, not a limitation.

Histological work by Hsu et al. (2014, Journal of Neurological Transmission) confirmed this using immunohistochemistry: at 2 weeks post-treatment, axonal architecture was disrupted; by 8 weeks, near-complete regeneration was visible — alongside a characteristic macrophage response consistent with Wallerian degeneration and nerve repair.

DURATION

How Long Does Relief Actually Last?

Clinical trial data — notably the Radnovich et al. 2017 randomized controlled trial in Osteoarthritis and Cartilage — demonstrates statistically significant, sustained pain relief out to 90 days. This is the FDA-cleared claim for iovera°.

In clinical practice, duration varies by anatomical target, proximity of treatment to the joint, and patient-specific biology. Outcomes frequently exceed the 90-day trial endpoint: 3–8 months in Knee Pain, 4–6+ months Shoulder Pain; 12–14 months Low Back Pain.

An important clinical insight: the more proximal the treatment point from the joint, the longer the nerve takes to regenerate to the target — effectively extending pain relief. Treating lumbar medial branches or knee genicular nerves farther from the articular surface can meaningfully prolong the duration of effect. This is something to thoughtfully individualize per patient.

For Meralgia Paresthetica (lateral femoral cutaneous nerve entrapment), relief duration in clinical experience can approach 1–2 years. Morton’s neuroma typically responds for 6–8 months per treatment cycle.

CLINICAL EVIDENCE

What Does the Research Show?

The evidence base for cryoneurolysis has grown substantially over the past decade, spanning joints, the spine, the chest wall, and the head. Below is a targeted summary of key studies informing current practice.

Knee Osteoarthritis

Radnovich et al. 2017 (Osteoarthritis and Cartilage) — the pivotal randomized, double-blind, sham-controlled trial of 180 patients — demonstrated statistically significant improvements in WOMAC outcomes at 6-month follow-up. Urban et al. 2021 (Arthroplasty Today, n=357) found no significant increase in postoperative infections when cryoneurolysis was performed two weeks preoperatively. Dasa et al. 2021 (Journal of Arthroplasty) found 45% less opioid usage in the treatment group at 6 and 12 weeks.

A 2024 real-world registry study in The Journal of Arthroplasty found that opioid-naïve patients receiving preoperative cryoneurolysis prior to TKA demonstrated improved pain scores, decreased opioid consumption, and meaningfully improved sleep disturbance over 6 months postoperatively.

Chronic Low Back Pain

A 2025 randomized pilot study in Pain Physician (30 patients) found that iovera° cryoneurolysis for facet-mediated chronic low back pain produced significantly lower pain scores at 180 days (3.1 vs. 5.4, p=0.01) compared to RFA, with functional disability also improving more substantially at one year. Functional outcomes on the Oswestry Disability Index were significantly lower with cryoneurolysis at 360 days.

Ankle Osteoarthritis

Perry et al. 2022 — a single-arm clinical trial of 40 patients with symptomatic ankle arthritis — demonstrated significant improvements in quality of life and pain scores following ultrasound-guided cryoneurolysis, an indication with historically limited non-surgical options.

Occipital Neuralgia

Kvarstein et al. 2019 (prospective multicenter, n=26): 70% of patients reported meaningful improvements and satisfaction at day 56. Grigsby et al. 2021 (double-blind randomized, n=52): greater than 50% improvement at 6–7 weeks in a controlled design.

Rib Fracture & Chest Wall Pain

Gabriel et al. 2020 — a sham-controlled RCT of 60 patients — demonstrated reduced opioid use and improved VAS scores. Multiple case series and pilot studies confirm cryoneurolysis’s role in reducing narcotic use in thoracic surgical and acute rib fracture contexts.

“Pain improvements can occur immediately and can last three months or more in the majority of cases — with meaningfully reduced opioid requirements in both surgical and non-surgical populations.”

PATIENT SELECTION

Who Is a Good Candidate?

Cryoneurolysis has one of the broadest applicability profiles of any interventional pain procedure I use. The right candidate is generally someone with a well-defined peripheral pain generator that can be accessed with a small-gauge needle under ultrasound guidance or anatomical localization. Conditions where I have observed particularly robust outcomes include knee arthritis (pre-operative, post-operative, and non-surgical), hip arthritis and labral pain via the PENG technique, shoulder arthritis and rotator cuff tendinopathy, ankle arthritis, Morton's neuroma, lumbar facet and sacroiliac joint pain, occipital neuralgia, cervicogenic headache, meralgia paresthetica, acute rib fracture, post-herpetic neuralgia, and spasticity-associated peripheral pain. The procedure is performed in a standard office or ambulatory surgery center setting under ultrasound guidance, takes minutes per target, and requires no sedation or fluoroscopy for most applications.

Absolute Contraindications

Cryoneurolysis should not be performed in patients with: open or infected wound at the treatment site, cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, or Raynaud’s disease.

SAFETY PROFILE

What Are the Risks?

Cryoneurolysis has a favorable safety profile that compares well against other interventional options. Key considerations:

Dysesthesias — Rare, and typically only noticed after the local anesthetic wears off. Most discomfort represents the expected Wallerian degeneration process rather than a complication. This typically resolves.

Thermal skin injury — Rare and straightforward to manage. The iovera° device includes an integrated skin warmer that significantly mitigates this risk.

Transient muscle weakness — Reported in a minority of shoulder cases when the suprascapular nerve is treated within the notch. Duration is generally 2–3 weeks maximum.

Unlocking new pain generators — Occasionally, effective treatment of one nerve reveals an underlying pain source previously masked. This is not a complication; it is a diagnostic opportunity and should be communicated to patients proactively.

Histological studies confirm preservation of local arteries, veins, sebaceous glands, hair follicles, and skin cells. Any transient muscle injury resolves within 2–3 weeks. This is a meaningfully clean safety profile for an interventional procedure.

FOR REFERRING CLINICIANS

Cryoneurolysis is increasingly supported as a component of multimodal perioperative pain management and as a durable non-opioid option for chronic pain states where traditional approaches have provided inadequate relief. Appropriate referral candidates include patients with arthritis of the knee, hip, shoulder, or ankle who have failed conservative management; patients awaiting joint replacement with modifiable surgical risk factors; patients with neuralgia or nerve-mediated pain syndromes; and patients where opioid minimization is a priority. I welcome direct physician-to-physician consultation.

PERSPECTIVE

A Note on Where This Fits in Modern Pain Medicine

We are in an era defined by two competing realities: a chronic pain epidemic that affects more than 50 million Americans, and a long-overdue cultural reckoning with opioid dependency. Procedures like cryoneurolysis represent a third path — not a medication, not a surgery, not a corticosteroid injection cycling through diminishing returns — but a mechanistically different tool that respects the biology of pain and the reversibility patients deserve.

I am particularly interested in its application for active, middle-aged adults — the runners, lifters, tennis players, and weekend warriors who are not ready for joint replacement, who don’t want chronic opioids, and for whom a 3–12 month window of meaningful pain relief represents the difference between continued athletic participation and forced retirement from the activities that define their quality of life.

This is not a final answer for every patient. But for the right patient, at the right time, with the right target — it works remarkably well. And that is worth knowing about.

DISCLOSURE & REFERENCES

This article is for educational purposes and reflects clinical experience and interpretation of published literature. It is not a substitute for individualized medical evaluation. Key references: Radnovich et al. 2017 (Osteoarthritis Cartilage); Urban et al. 2021 (Arthroplasty Today); Dasa et al. 2021 (J Arthroplasty); McMillan et al. 2023 (Surg Technol Int); Gabriel et al. 2020 (RCT, rib); Perry et al. 2022 (ankle); Kvarstein et al. 2019 (occipital); Grigsby et al. 2021 (occipital RCT); Hsu et al. 2014 (J Neurol Trans); Ferillo ASRA 2024; Guynn et al. 2025 (Pain Physician).

ABOUT THE AUTHOR

Dr. Mahajer is a double board-certified physiatrist and sports medicine physician, fellowship-trained in Interventional Spine & Sports Medicine at the Icahn School of Medicine at Mount Sinai. He is an Assistant Professor of Neuroscience at FIU Herbert Wertheim College of Medicine. He is the Immediate Past President of the American Osteopathic College of Physical Medicine and Rehabilitation (AOCPMR), holds medical licenses in Florida, New York, and California, and has been recognized as a Top Physiatrist and Top Doctor in both Florida and New York.